FGFR2 and infantile convulsions and choreoathetosis: In a phase I/II trial, derazantinib’s ORR was 21%, DCR was 82.8%, and it exhibited a median PFS 5.7 months in 29 advanced iCCA patients with FGFR2 fusion [43].